Merit Medical Systems (FRA:MM3) ROCE %: 9.77% (As of Mar. 2026)

What is Merit Medical Systems ROCE %?

Merit Medical Systems FRA:MM3 +1.74% 86 ROCE % is 9.77% as of Mar. 2026. GuruFocus rates FRA:MM3 with a GF Score™ of 86/100 and a GF Value™ of €81.73 (Modestly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Merit Medical Systems's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.77%.

Merit Medical Systems (FRA:MM3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Merit Medical Systems ROCE % Related Terms

Merit Medical Systems ROCE % Historical Data

* Premium members only.

The historical data trend for Merit Medical Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merit Medical Systems ROCE % Chart

Merit Medical Systems Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

4.25

6.43

7.07

8.55

8.04

Merit Medical Systems Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															7.84	8.39	7.54	9.49	9.77

86GF Score

Merit Medical Systems Inc FRA:MM3

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Merit Medical Systems ROCE % Calculation

Merit Medical Systems's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	168.578	/	( ( (2309.766 - 206.664)	+	(2293.777 - 204.758) )	/ 2 )
	=	168.578	/	( (2103.102	+	2089.019)	/ 2 )
	=	168.578	/	2096.0605
	=	8.04 %

Merit Medical Systems's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	207.848	/	( ( (2293.777 - 204.758)	+	(2352.181 - 187.596) )	/ 2 )
	=	207.848	/	( ( 2089.019	+	2164.585 )	/ 2 )
	=	207.848	/	2126.802
	=	9.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 9.77% mean?

Merit Medical Systems (FRA:MM3) has a ROCE % of 9.77% as of Mar. 2026.

Is Merit Medical Systems' ROCE % too high?

Merit Medical Systems' current ROCE % is 9.77%. The Medical Devices & Instruments industry median ROCE % is 2.23. Merit Medical Systems' value of 9.77% is 338.1% above this industry median. Overall, Merit Medical Systems has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Merit Medical Systems' ROCE % compare to NVST and MMED?

Merit Medical Systems' ROCE % of 9.77% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Merit Medical Systems' value of 9.77% is 338.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merit Medical Systems's current ROCE % of 9.77% is 338.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merit Medical Systems's current ROCE % is 9.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Merit Medical Systems stock overvalued right now?

Based on GuruFocus' analysis, Merit Medical Systems (FRA:MM3) is currently considered Modestly Undervalued. The stock's GF Value™ is €81.73, compared to a current price of €58.50 — trading 28.4% below its estimated fair value. The current ROCE % is 9.77% and 338.1% above the Medical Devices & Instruments industry median of 2.23. Merit Medical Systems' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Merit Medical Systems (FRA:MM3), the current ROCE % is 9.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merit Medical Systems (FRA:MM3) Overvalued in 2026?

Based on GuruFocus' analysis, Merit Medical Systems stock appears to be undervalued. The current stock price of €58.50 is trading 28.4% below its estimated GF Value™ of €81.73. GuruFocus considers Merit Medical Systems to be Modestly Undervalued.

Key valuation signals for FRA:MM3:

ROCE %: 9.77%
GF Value™: €81.73 vs. price of €58.50 (28.4% below fair value)
GF Score™: 86/100
Industry Position: 338.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:MM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merit Medical Systems Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies NVST MMED ICUI WRBY STVN LMAT XRAY TFX PLSE NNNN ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges MMSI:USA

Address 1600 West Merit Parkway, South Jordan, UT, USA, 84095

Website https://www.merit.com

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

86GF Score

Get the complete analysis for FRA:MM3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.50

Price

€81.73

GF Value

View FRA:MM3 Analysis

See ROCE % data for all stocks →